<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400567</url>
  </required_header>
  <id_info>
    <org_study_id>NeoPal - UC-0140/1404</org_study_id>
    <secondary_id>2014-002560-33</secondary_id>
    <secondary_id>CARMINA04</secondary_id>
    <secondary_id>NEOPAL</secondary_id>
    <nct_id>NCT02400567</nct_id>
  </id_info>
  <brief_title>Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women</brief_title>
  <acronym>NeoPAL</acronym>
  <official_title>Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NanoString Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose in the present study an innovative approach, combining the most&#xD;
      recent therapeutic opportunities in high risk ER+ breast cancer with the most recent and&#xD;
      innovative diagnostic approaches such as the PAM50 signature and the RCB tumor response&#xD;
      evaluation method. In line with the most recent recommendations on targeted anticancer&#xD;
      therapies, the investigators have designed a parallel phase II randomized trial with early&#xD;
      stopping rules 26, which will able in the meantime to build a unique prospective collection&#xD;
      of tumor tissue, pre- and post-treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the number of patients with a Residual Cancer Burden (RCB) 0-I index as a measure of efficacy</measure>
    <time_frame>21 weeks</time_frame>
    <description>Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. 6 variables are included in a calculation formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical response in each treatment arm as defined by clinical and ultrasound examination.</measure>
    <time_frame>21 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the number and type of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>21 weeks</time_frame>
    <description>The toxicity will be evaluated according to the scale CTC-AE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the PAM50 risk of recurrence (ROR) score to its ability to predict RCB as defined in outcome 1</measure>
    <time_frame>21 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the rates of breast conservation therapy in the two arms with regard to the initially planned surgery.</measure>
    <time_frame>21 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Neoadjuvant Operable Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole Palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs: letrozole + palbociclib combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracile</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole Palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <arm_group_label>Letrozole Palbociclib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years, Post-menopausal women&#xD;
&#xD;
          2. Newly diagnosed and operable unilateral invasive breast cancer, not candidate or&#xD;
             uncertain for breast conservation - Note: Multicentric/multifocal tumors are allowed&#xD;
             provided a maximum of 3 lesions are present, and all share the same characteristics:&#xD;
             ER Allred 4, Her2- (PAM50 will be performed in the largest lesion)&#xD;
&#xD;
          3. Stage II-IIIA&#xD;
&#xD;
          4. Assessment of nodal status available (Ultrasound guided FNA or biopsy if necessary)&#xD;
&#xD;
          5. Non metastatic, M0&#xD;
&#xD;
          6. ER-positive by IHC (Allred Score≥4)&#xD;
&#xD;
          7. HER2-negative by IHC (score 0 or 1+) and/or Fish/Cish&#xD;
&#xD;
          8. Either Luminal A AND proven nodal involvement (cytology or histology), or Luminal B&#xD;
             through PAM50 ROR (Prosigna™) centralized evaluation&#xD;
&#xD;
          9. ECOG 0-1&#xD;
&#xD;
         10. No prior systemic therapy for the present tumor&#xD;
&#xD;
         11. Adequate renal, hepatic, and hematopoietic functions as defined by the following&#xD;
             criteria:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1,500/mm3 or ≥1.5 x 109/L&#xD;
&#xD;
               -  Platelets ≥100,000/mm3 or ≥100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Serum Aspartate Transaminase (AST) and serum Alanine Aminotransferase&#xD;
                  Transaminase (ALT) ≤2.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Alkaline phosphatase ≤2.5 x ULN&#xD;
&#xD;
               -  Total serum bilirubin ≤1 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x ULN or estimated creatinine clearance ≥ 60 mL/min as&#xD;
                  calculated using the method standard for the institution&#xD;
&#xD;
         12. Adequate cardiac functions, including:&#xD;
&#xD;
               -  12 Lead electrocardiogram (ECG) with normal tracing or non clinically significant&#xD;
                  changes that do not require medical intervention.&#xD;
&#xD;
               -  QTc interval ≤480 msec&#xD;
&#xD;
               -  No history of Torsades de Pointes or other symptomatic QTc abnormality.&#xD;
&#xD;
         13. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and other trial procedures&#xD;
&#xD;
         14. Signed informed consent and health insurance coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non operable, bilateral, T4 or metastatic breast cancer&#xD;
&#xD;
          2. Limited T2 breast cancer immediately accessible to conservative surgery&#xD;
&#xD;
          3. Previous homolateral breast cancer (including in situ carcinoma), and/or contralateral&#xD;
             breast cancer except if treated by surgery +/- radiation therapy alone without any&#xD;
             systemic treatment&#xD;
&#xD;
          4. Previous hormone replacement therapy (HRT) stopped less than 2 weeks before beginning&#xD;
             of treatment&#xD;
&#xD;
          5. Previous use of SERMs such as raloxifene&#xD;
&#xD;
          6. Any surgery (not including minor procedures such as lymph node biopsy, primary tumor&#xD;
             core biopsy, fine needle aspiration) within 4 weeks of start of study treatment; or&#xD;
             not fully recovered from any side effects of previous procedures.&#xD;
&#xD;
          7. Diagnosis of any previous malignancy within the last 5 years, except for adequately&#xD;
             treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical&#xD;
             carcinoma&#xD;
&#xD;
          8. History of any previous anti-cancer chemotherapy and any previous treatment using AI&#xD;
&#xD;
          9. Concurrent administration of herbal preparations as complementary medicine.&#xD;
&#xD;
         10. Any clinically significant gastrointestinal abnormalities, which may impair intake,&#xD;
             transit or absorption of the study drugs, such as the inability to take oral&#xD;
             medication in tablet form and malabsorption syndrome&#xD;
&#xD;
         11. Patient with any psychological, familial, social or geographical condition which could&#xD;
             potentially hamper compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Cottu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzette Delaloge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave roussy, Villejuif</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30307466/</url>
    <description>Ann Oncol . 2018 Dec 1;29(12):2334-2340. doi: 10.1093/annonc/mdy448</description>
  </link>
  <results_reference>
    <citation>Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018 Dec 1;29(12):2334-2340. doi: 10.1093/annonc/mdy448.</citation>
    <PMID>30307466</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Luminal</keyword>
  <keyword>Post menopausal</keyword>
  <keyword>Breast conservation</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.</ipd_time_frame>
    <ipd_access_criteria>The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

